Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000665854 | SCV000790042 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2017-03-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001861747 | SCV002233696 | pathogenic | not provided | 2022-10-04 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 550947). Disruption of this splice site has been observed in individual(s) with Usher syndrome (PMID: 21569298). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This sequence change affects an acceptor splice site in intron 53 of the USH2A gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is present in population databases (rs370327669, gnomAD 0.0009%). For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. |
Genome- |
RCV003446297 | SCV004172016 | likely pathogenic | Retinitis pigmentosa 39 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003446296 | SCV004172017 | likely pathogenic | Usher syndrome type 2A | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003446297 | SCV004206431 | likely pathogenic | Retinitis pigmentosa 39 | 2022-03-30 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV004817871 | SCV005069428 | pathogenic | Retinal dystrophy | 2017-01-01 | criteria provided, single submitter | clinical testing |